Prospective studies involving larger numbers of patients are needed to further evaluate the clinical utility of podoplanin as a biomarker for laryngeal cancer risk assessment providing additional value beyond the clinical and histological markers. This evidence concerns the gene PDPN and laryngeal carcinoma.